CD4 Antibody (ibalizumab) - Humanized, IgG4SP
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28350
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Human IgG4 Clone # ibalizumab
Concentration
LYOPH mg/ml
Product Specifications
Immunogen
CD4
Reactivity Notes
Predicted species reactivity: Cynomolgus
Clonality
Monoclonal
Host
Human
Isotype
IgG4
Endotoxin Level
< 0.001EU/ug,determined by LAL method.
Description
Expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Also known as 'ibalizumab'.
IgG4SP is human IgG4 with S228P mutation.
Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Also known as 'ibalizumab'.
IgG4SP is human IgG4 with S228P mutation.
Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Scientific Data Images for CD4 Antibody (ibalizumab) - Humanized, IgG4SP
Functional: CD4 Antibody (ibalizumab) - Humanized, IgG4SP[NBP3-28350] -
CD4 Antibody (ibalizumab) - Humanized, IgG4SP Activation inhibition was evaluated using PBMC. The max induction fold was approximately 1.71
Functional: CD4 Antibody (ibalizumab) - Humanized, IgG4SP[NBP3-28350] -
CD4 Antibody (ibalizumab) - Humanized, IgG4SP Pseudoviral inhibition was evaluated using Tzmbl.The IC50 was approximately 0.441 nM.
Flow Cytometry: CD4 Antibody (ibalizumab) - Humanized, IgG4SP[NBP3-28350] -
Human CD4 CHO cells were stained with CD4 Antibody (ibalizumab) - Humanized, IgG4SP and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.16 ug/mL.Applications for CD4 Antibody (ibalizumab) - Humanized, IgG4SP
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Reconstitution
Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
Formulation
Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
Preservative
No Preservative
Concentration
LYOPH mg/ml
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: CD4
Given its critical role in T cell development, CD4 also has diverse immunology-related functions. CD4 acts as a coreceptor with the T-cell receptor (TCR) during T cell activation and thymic differentiation by binding directly to major histocompatibility complex (MHC) class II antigens and associating with the protein tyrosine kinase, Lck (4). This interaction contributes to the formation of the immunological synapse (5). Defects in antigen presentation cause dysfunction of CD4+ T cells and the almost complete loss of MHC II expression on B cells in peripheral blood, as observed in severe combined immunodeficiency (SCID) (6). CD4 also functions as a receptor for the human immunodeficiency virus (HIV) by binding to gp120, the envelope glycoprotein of HIV-1. It has been shown that the V-like domains are critical for binding to gp120 (7). In immune mediated and infectious diseases of the central nervous system, CD4 functions as an indirect mediator of neuronal damage (8).
References
1. Omri, B., Crisanti, P., Alliot, F., Marty, M., Rutin, J., Levallois, C., . . . Pessac, B. (1994). CD4 expression in neurons of the central nervous system. International Immunology, 6(3), 377-385. doi:10.1093/intimm/6.3.377
2. Wan, Y. Y., & Flavell, R. A. (2009). How diverse-CD4 effector T cells and their functions. Journal of Molecular Cell Biology, 1(1), 20-36. doi:10.1093/jmcb/mjp001
3. Wu, H., Myszka, D. G., Tendian, S. W., Brouillette, C. G., Sweet, R. W., Chaiken, I. M., & Hendrickson, W. A. (1996). Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Proceedings of the National Academy of Sciences, 93(26), 15030-15035. doi:10.1073/pnas.93.26.15030
4. Doyle, C., & Strominger, J. L. (1987). Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature, 330, 256-259. doi:10.1038/330256a0
5. Vignali, D. A. (2010). CD4 on the road to coreceptor status. The Journal of Immunology, 184(11), 5933-5934. doi:10.4049/jimmunol.1090037
6. Tasher, D., & Dalal, I. (2012). The genetic basis of severe combined immunodeficiency and its variants. The Application of Clinical Genetics, 5, 67-80. doi:10.2147/tacg.s18693
7. Arthos, J., Deen, K. C., Chaikin, M. A., Fornwald, J. A., Sathe, G., Sattentau, Q. J., . . . Sweet, R. W. (1989). Identification of the residues in human CD4 critical for the binding of HIV. Cell, 57(3), 469-481. doi:10.1016/0092-8674(89)90922-7
8. Buttini, M., Westland, C. E., Masliah, E., Yafeh, A. M., Wyss-Coray, T., Mucke, L. (1998). Novel role of human cd4 molecule identified in neurodegeneration. Nature Medicine, 4(4), 441-446. doi:10.1038/nm0498-441
Additional CD4 Products
Product Documents for CD4 Antibody (ibalizumab) - Humanized, IgG4SP
Product Specific Notices for CD4 Antibody (ibalizumab) - Humanized, IgG4SP
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...